Research by the ALL group will allow doctors to provide more specific treatments for patients that have certain genetic changes
Jordi Ribera and Dr Josep Maria Ribera have published a paper that will have important consequences for patients in treatment for Acute Lymphoblastic Leukaemia (ALL).
A New Publication Describes how the Notch Ligand DLL4 Identifies and Regulates the Fate of Haemapoietic Stem Cells
The Stem Cells, Mesenchymal Cancer and Development Group, led by Pablo Menéndez has published a new paper in the prestigious journal Leukemia, one of the Nature Group publications.
A new paper validates WPSS for Myelodysplastic Syndromes and provides relevant in formation for the implementation of risk-adapted strategies in MDS
Dr Francesc Solé, leader of the Myelodysplastic Syndrome group at the Josep Carreras Research Institute has taken part in an international study. The publication establishes a new international benchmark indicator to improve the prognostic stratification of patients suffering myelodysplastic syndromes (MDS).
A new study examines the effect of HIV infection on patients being treated for a type of Non-Hodgkin’s Lymphoma called aggressive B-cell lymphoma with immuno-chemotherapy
A study carried out at the ICO-Germans Trias Campus shows that HIV-infected patients have the same chance of being cured of aggressive B-cell lymphoma than those who are HIV-negative
The European Research Council recognizes the Josep Carreras Leukaemia Research Institute awarding a prestigious Consolidator Grant to Pablo Menéndez
Pablo Menéndez has been awarded a European Research Council Consolidator Grant for his project Genomic, Cellular and Developmental Reconstruction of Infant MLL-AF4+ Acute Lymphoblastic Leukaemia.
Phase 1 of the new building is well underway
After the successful preparation of the site and the construction of the foundations and vertical supports Phase 0 finished on time.
New progress in the treatment of multiple myeloma patients in relapse
The Josep Carreras Leukaemia Research Institute, together with the Catalan Oncology Institute (ICO) in Badalona, takes part in a new study to improve survival in multiple myeloma patients who don’t respond to regular treatments.
The José Carreras Foundation allocates one million euros for joint research projects between Spanish and German scientists
The German headquarter of the José Carreras Foundation (Deutsche Josep Carreras Leukämie Stiftung) has allocated around one million euros to fund four research projects of the Josep Carreras Leukaemia Research Institute carried out in collaboration with German scientists.
These projects, which will be developed at the Campuses Clinic UB and ICO-Germans Trias i Pujol of the Josep Carreras Leukaemia Research Institute, CERCA centre of the Catalan Government, aim to perform basic, translational and clinical research in the field of leukaemia and other haematological malignancies, especially myelodysplastic syndromes.
Josep Mª Ribera of the Acute Lymphoblastic Leukemia Group at the Institute has participated in a study showing that Blinatumomab is a successful treatment for patients with relapsed refractoryB-precursor ALL
Dr. Josep Mª Ribera, Head of the Haematology Clinical Unit in the Catalan Institute of Oncology I (ICO) at the Trias i Pujol Hospital in Badalona (Barcelona) and collaborator in several IJC projects has published the article "Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study" in the Lancet